SCHEMBL19808807

SCHEMBL19808807

COC(=O)c1ccc(Oc2cccc(C(C)(C)C)c2C(C)Br)nc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.41
▸ MAPK1 P28482 4/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ GRN P28799 2/20 0.36
▸ SORT1 Q99523 2/20 0.36
▸ GALR3 O60755 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ GABRA5 P31644 6/20 0.35
▸ MAPT P10636 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ P2RX3 P56373 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19808815 0.84 HRH3 (0.47) LMNAMAPK1KDM4EL3MBTL1HRH3
SCHEMBL19808820 0.83 MAPK1 (0.39) LMNAMAPK1KDM4EL3MBTL1HRH3
SCHEMBL19808857 0.76 LMNA (0.46) LMNAMAPK1KDM4EL3MBTL1HRH3
SCHEMBL19808889 0.73 LMNA (0.42) LMNAMAPK1KDM4EL3MBTL1HRH3
SCHEMBL19808827 0.73 HRH3 (0.48) LMNAMAPK1KDM4EL3MBTL1HRH3
SCHEMBL19808916 0.72 MAPK1 (0.42) LMNAMAPK1KDM4EL3MBTL1ALOX5AP
SCHEMBL23699642 0.71 XDH (0.42) MAPK1L3MBTL1HRH3MAPT
SCHEMBL19808903 0.71 LMNA (0.45) LMNAMAPK1KDM4EL3MBTL1RAB9A
SCHEMBL19808863 0.71 P2RX3 (0.45) LMNAMAPK1KDM4EL3MBTL1HRH3
SCHEMBL19808831 0.71 LMNA (0.56) LMNAMAPK1KDM4EL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275881-B1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) 2021-08-04 — — EP disclosed
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-10-16 — — US disclosed
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 — — US disclosed
EP-3275881-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) 2018-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF HIF1AN, EGLN3, EGLN2 LMNA 2733/4885MAPK1 2748/4885KDM4E 673/4885
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof HIF1AN, EGLN3, EGLN2 LMNA 2733/4885MAPK1 2748/4885KDM4E 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback